Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash from Financing Activities (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Cash from Financing Activities for 11 consecutive years, with $12.7 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 628.67% to $12.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.9 million through Dec 2025, up 115.38% year-over-year, with the annual reading at $13.9 million for FY2025, 115.38% up from the prior year.
  • Cash from Financing Activities hit $12.7 million in Q4 2025 for Seres Therapeutics, up from $61000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $98.0 million in Q3 2022 to a low of -$110.9 million in Q3 2024.
  • Historically, Cash from Financing Activities has averaged $7.0 million across 5 years, with a median of $1.6 million in 2023.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 44651.54% in 2023 and later crashed 7783.37% in 2024.
  • Year by year, Cash from Financing Activities stood at -$780000.0 in 2021, then surged by 689.36% to $4.6 million in 2022, then soared by 39.85% to $6.4 million in 2023, then crashed by 72.98% to $1.7 million in 2024, then surged by 628.67% to $12.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for MCRB at $12.7 million in Q4 2025, $61000.0 in Q3 2025, and $1.2 million in Q1 2025.